A 2.5-year-old girl with neurogenic Gaucher's disease was transplanted with donor bone marrow from her HLA-compatible 12-year-old brother whose marrow was harvested 30 min post-mortem, after he suffered a severe head and neck injury. The marrow was stored in liquid nitrogen for 30 days prior to infusion. The posttransplantation period was uneventful with good engraftment and no signs of graft-versus-host disease. Currently, 6 months post-allogeneic bone marrow transplantation (alloBMT), analysis of both bone marrow and blood samples by PCR documented only cells of donor origin. This case demonstrates the feasibility of cadaveric marrow as a source of donor cells. To our knowledge, this patient is the only survivor of alloBMT from a cadaveric donor.
Gaucher's disease, a lysosomal disorder resulting from a deficiency in ␤-glucocerebrosidase, has been successfully treated by allogeneic bone marrow transplantation (alloBMT). [1] [2] [3] With the development of enzyme replacement therapy, the number of patients in need of alloBMT has decreased substantially. Nevertheless, due to its large molecular weight, ␤-glucocerebrosidase may not penetrate the blood-brain barrier, and therefore patients with neurogenic disease will not necessarily benefit from replacement therapy. These patients and non-responders to exogenously administered enzyme are still dependent on alloBMT for normal survival. However, only 30-40% of patients have available histocompatible siblings, 4 therefore strategies have to be developed to find alternative donors. The use of cadaveric donor marrow could be an important step in providing an expanded donor pool.
Case report
A 2.5-year-old girl presented with massive hepatosplenomegaly and strabismus and reduced ␤-glucocerebrosidase activity in blood mononuclear cells. Neuropathic Gaucher's Correspondence: Dr J Kapelushnik, Department of BMT, Hadassah University Hospital, POB 12000, Jerusalem 91120, Israel Received 21 August 1997; accepted 11 November 1997 disease was diagnosed based on the detection of a homozygous mutation in the ␤-glucocerebrosidase gene at location 1448/1448. Her 12-year-old brother was found to be fully compatible at both class I and class II MHC-loci by serology and DNA studies and did not carry the genetic mutation for Gaucher's disease.
Three weeks prior to the scheduled alloBMT, before marrow harvesting, he suffered a severe head trauma with massive brain injury. After cessation of cardio-pulmonary resuscitation, 20 000 units of heparin were injected followed by cardiac massage for 5 min to prevent post-mortem hyper-coagulation. By aspiration from the posterior iliac crest 950 ml of bone marrow cells were harvested, processed, cryopreserved and stored in liquid nitrogen (−196°C). Bone marrow samples were subsequently analyzed for bacterial and viral contamination and their viability tested. Cells were found to be sterile, with a viability post-thawing of 82% as determined by trypan blue dye exclusion. Colony-forming assays (CFU-GM) were within the normal range (from fresh cells 25 colonies/ 2 × 10 5 MNC, from frozen cells 16 colonies/2 x 10 5 MNC). Pre-transplant conditioning consisted of fludarabine (30 mg/m 2 /day i.v. × 6), busulfan (4 mg/kg/day, 1 mg/kg 96 h) and anti-T lymphocyte globulin (Fresenius) (10 mg/kg × 4). On the day of transplant, the patient received 23.3 × 10 6 CD34 cells/kg (7.5 × 10 8 MNC/kg). Cyclosporin A (3 mg/kg) was administered intravenously starting on day −1 as graft-versus-host prophylaxis. Procedure-related complications were mild with very mild mucositis and fever that resolved on day +20 post-BMT. Early engraftment (day +15) of male cells was detected by amelogenin (AMG)-PCR. 5 Absolute neutrophil counts were Ͼ0.5 × 10 9 /l on day +11 and platelet counts reached Ͼ20 × 10 long been proposed as a suitable source of marrow for transplantation, it has rarely been used for this purpose. 6, 7 In 1957, Thomas et al 8 attempted the first cadaveric marrow infusion that resulted in temporary erythrocyte engraftment. Ever since, the properties and characteristics of cadaveric marrow have been studied. In fact, it was shown that marrow removed up to 6 h post-mortem still contained adequate numbers of viable stem cells. 9 The only other partially successful case of cadaveric marrow transplantation described to our knowledge, was a child with ALL who received a graft from his deceased father. Although engraftment took place, the patient succumbed to acute GVHD. 10 Cadaveric marrow has already been shown to improve donor-specific tolerance in cadaveric renal allograft recipients and was associated with improved allograft survival. 11 The availability of cadaveric marrow is cost-effective. A high number of donor stem cells can be obtained, especially for a haploidentically mismatched allograft which is of considerable importance. However, the use of cadaveric marrow has so far not been expanded, due to the large number of unrelated mismatched donors available. Over the last years, many centers established cord blood banks which may ease the dependence on matched related donors even further. However, the major problem with cord blood grafts
has not yet been solved. Due to the relatively low number of stem cells, transplantation of cord blood in older patients may not be feasible. Bone marrow harvests from cadavers on the other hand yield very high numbers of viable cells. In contrast to marrow obtained from live donors, the surgical procedure used in cadavers also reduces the number of T cells in the harvested cells which may in turn lower the incidence of GVHD. 7 Based on the published experience and the case described here, cadaveric marrow can be used as a unique source for alloBMT. We therefore suggest establishing unrelated cadaveric bone marrow banks that would, in parallel with the banks of unrelated cord blood, serve as sources for allogeneic stem cell transplantations.
